Combinatorx and Bio*One Capital Establish Combinatorx Singapore for Infectious Disease Product Discovery and Development
Sir David Lane to join the Board of Directors of CombinatoRx Singapore
As a drug development company, CombinatoRx Singapore will focus on developing a range of preclinical and clinical development capabilities. Located at the Biopolis in Singapore, CombinatoRx Singapore has plans to employ approximately twenty full-time researchers and is expected to commit US$20 million to the development of novel drug candidates for infectious diseases.
In addition, CombinatoRx Singapore and Bio*One Capital announced that Sir David Lane will join the Board of Directors of CombinatoRx Singapore. "We are proud to have attracted an individual of such high caliber to CombinatoRx Singapore's Board of Directors," said Alexis Borisy, President and CEO of CombinatoRx. "His extensive research and industry experience, and leadership in molecular and cell biology research will be extremely valuable as CombinatoRx Singapore works towards advancing the discovery, development and commercialization of its product candidates in Singapore."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.